Inside information: Solwers has agreed on temporary waiver under its financing agreement

Solwers said its main bank waived review of the company’s net debt/EBITDA covenant at the 30 June 2026 testing date after negotiations to address a potential covenant breach. The company will continue financing discussions with its lender, following its 17 June warning that it did not expect to meet the covenant. The update reduces near-term default pressure, but leverage and refinancing risk remain in focus.

Analysis

The key signal here is not the waiver itself, but that the lender has effectively converted an imminent technical default into a negotiation process. That reduces near-term forced-selling risk, but it does not fix the capital structure; it simply buys time and increases the probability that value migrates from equity toward the bank through tighter terms, fees, collateral, or amortization. In stressed small-cap credits, covenant relief often marks the point where enterprise value becomes increasingly hostage to liquidity runway rather than operating performance.

Second-order effects likely matter more than the headline. Once a bank grants flexibility on one test date, suppliers and counterparties tend to reassess creditworthiness within days, even if no formal event has occurred; that can show up as shorter payment terms, advance payment requests, or project bid caution. If Solwers is operating in a services-heavy model, the risk is not only refinancing but also margin compression from working-capital drag, which can persist for multiple quarters even if the bank remains supportive.

The market is likely underpricing the distinction between covenant relief and balance-sheet repair. A waiver usually extends the equity optionality by weeks or months, but it also signals the bank has enough leverage to dictate restructuring economics later; that asymmetry favors creditors unless there is a clear operational inflection. The real catalyst sequence is: next covenant negotiations, any revised EBITDA guidance, and whether working capital stabilizes before the next testing cycle.

Contrarian view: the stock may not be “too cheap” just because a default was avoided. In these situations, the better risk/reward often comes from waiting for either a confirmed refinancing package or a liquidity event that creates a cleaner entry; until then, any rally can be a trap if the next update reveals more aggressive terms. If management can show stabilized cash conversion over the next 1-2 reporting periods, the setup improves materially, but absent that, the bank’s waiver is a delay mechanism, not a thesis breaker.

Key Decisions for Investors

• Avoid initiating long equity exposure in the next 1-2 weeks; the waiver reduces immediate blow-up risk but leaves downside open if the next financing update includes dilution or collateralization.
• If borrow is available, consider a tactical short in the equity on any relief rally over the next 5-10 trading days; risk/reward favors fading bounce moves until financing terms are made explicit.
• Watch for supplier stress indicators and working-capital disclosures over the next quarter; if DSO rises or payables extend materially, that is a stronger short signal than the covenant waiver itself.
• For event-driven credit accounts, look for a relative-value long in the bank loan / short equity pair only if new terms materially improve lender recovery while preserving equity dilution risk.